MicroRNAs as a biomarker in lung cancer
Tarih
2023Yazar
Canatan, Duran
Sönmez, Yonca
Yılmaz, Özlem
Coşkun, Hasan Şenol
Göksu, Sema Sezgin
Uçar, Selda
Aktekin, Mehmet Rıfkı
Üst veri
Tüm öğe kaydını gösterÖzet
Introduction: Lung cancer (LC) is the most common cancer in the world.Well known causes are
long term smoking, environmental influences and genetic variations. LC is divided into two main types based
on their histological phenotypes; small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC).
The high specificity of these new screening methods, which are non-invasive, safe, inexpensive and simple to
perform, is important in the early diagnosis and prognosis of cancer. MicroRNAs are significant biomarkers
on the diagnosis metastasis and targeted therapies of NSCLC. In our study, we aimed to investigate the
potential
of using microRNAs as a biomarker in the early diagnosis of lung cancer. Patients and methods:
Twenty patients diagnosed with lung cancer and twenty healthy individuals of the same age and gender were
selected as the control group. Sixteen microRNAs were studied from blood samples. Results: Sixteen miRNAs
(Let -7c, Let-7g, miR-1, miR-21, miR-29a, miR-31, miR-34a, miR 103a, miR-141, miR-155, miR-193b,
miR-200b, miR-205, miR-340, miR-486, miR-708) were selected for tests and MiR 181 and miR 192 were
used as the endogenous control group in line with their binding potentials and gene expression levels. The
most specific and sensitive miRNAs were mirR-29a, miR-103a, and miR486 according to endogen controls
in patients and healthy volunteer subjects. Discussion: A meta-analysis study showed that circulating miRNAs
could be promising biomarkers for early diagnosis of lung cancer. Overall, 17 studies were included evaluating
35 miRNA markers and 19 miRNA panels in serum or plasma. Conclusion: In conclusion, there is a need for
further validation studies for the use of three miRNAs as a biomarker in the early diagnosis and prognosis of
lung cancer. (www.actabiomedica.it)